Recent advances in biomarkers for senescence: Bridging basic research to clinic

In this review, we review the current status of biomarkers for aging and possible perspectives on anti‐aging or rejuvenation from the standpoint of biomarkers. Aging is observed in all cells and organs, and we focused on research into senescence in the skin, musculoskeletal system, immune system, and cardiovascular system. Commonly used biomarkers include SA‐βgal, cell‐cycle markers, senescence‐associated secretory phenotype (SASP) factors, damage‐associated molecular patterns (DAMPs), and DNA‐damage‐related markers. In addition, each organ or cell has its specific markers. Generally speaking, a combination of biomarkers is required to define age‐related changes. When considering the translation of basic research, biomarkers that are highly sensitive, highly specific, with validation and reliability as well as being non‐invasive are optimal; however, currently reported markers do not fulfill the prerequisite for biomarkers. In addition, rodent models of aging do not necessarily represent human aging, and markers in rodent or cell models are not applicable in clinical settings. The prerequisite of clinically applicable biomarkers is that they provide useful information for clinical decision‐making, such as predicting disease risk, diagnosing disease, monitoring disease progression, or guiding treatment decisions. Therefore, the development of non‐invasive robust, reliable, and useful biomarkers in humans is necessary to develop anti‐aging therapy for humans. Geriatr Gerontol Int 2025; ••: ••–•• .